A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria

Journal of Allergy and Clinical Immunology

Volumn 104, Issue 5, 1999, Pages 1071-1078

  Finn Jr , Albert F ^a,c   Kaplan, Allen P ^a   Fretwell, Richard ^b   Qu, Roger ^b   Long, Joseph ^b  

^a Allerg Asthma Centers C   (United States)

^b SANOFI   (France)

^c NONE   (United States)

Author keywords

Antihistamine; Chronic idiopathic urticaria; Fexofenadine HCl; Pruritus; Wheals

Indexed keywords

FEXOFENADINE; PLACEBO;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC URTICARIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; VOMITING;

EID: 0032755849     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(99)70091-6     Document Type: Article

References (26)

1. 1. Greaves MW. Chronic urticaria. N Engl J Med 1995;322:1767-72.
2. 2. Fox RW. Update on urticaria and angioedema (hives). Allergy Proc 1995;16:289-92.
3. 3. O'Donnell BF, Lawler F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on quality of life. Br J Dermatol 1997;136:197-201.
4. 4. Leung DYM, Diaz LA, DeLeo V, Soter NA. Allergic and immunologic skin disorders. JAMA 1997;278:1914-23.
5. 5. Charlesworth EN, editor. The spectrum of urticaria. Immunol Allergy Clin North Am 1995;15:641-56.
6. 6. Kobza Black A. The pathogenesis of urticaria. Keio J Med 1997;46:37-9.
7. 7. Natbony SF, Philips ME, Elias JM, Godfrey HP, Kaplan AP. Histologic studies of chronic idiopathic urticaria. J Allergy Clin Immunol 1983;71:177-83.
8. 8. Elias J, Boss E, Kaplan AP. Studies of the cellular infiltrate of chronic idiopathic urticaria: prominence of T-lymphocytes, monocytes, and mast cells. J Allergy Clin Immunol 1986;87:914-8.
9. 9. Sabroe RA, Puon E, Orchard GE, Lane D, Francis DM, Barr RM, et al. Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: comparison of patients with and without anti FceRI or anti IgE autoantibodies. J Allergy Clin Immunol 1999;103:484-93.
10. 10. Peters MS, Schrueter AL, Kephart GM. Localization of eosinophil granule major basic protein in chronic urticaria. J Invest Dermatol 1983;81:39-43.
11. 11. Hide M, Francis DM, Grattan CEH, Hakimi JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993;328:1599-1604.
12. 12. Ferrer M, Kinet J-P, Kaplan AP. Comparative studies of functional and binding assays for IgG anti FceRIα (α subunit) in chronic urticaria. J Allergy Clin Immunol 1998;101:672-6.
13. 13. Fiebiger E, Maurer D, Holub H, Reininger B, Hartmann G, Woisetschlager M, et al. Serum IgG autoantibodies directed against the α chain of FceRI: a selective marker and pathogenic factor for a distinct subset of chronic urticaria patients. J Clin Invest 1995;96:2606-12.
14. 14. Greaves MW, Sabroe RA. ABC of allergies: allergy and the skin. 1-urticaria. BMJ 1998;316:1147-50.
15. 15. Soter NA. Uticaria: current therapy. J Allergy Clin Immunol 1990;86:1009-14.
16. 16. Greaves MW, Sabroe RA. Histamine: the quintessential mediator. J Dermatol 1996;23:735-40.
17. 17. Simons FER, Simons KJ. Peripheral H1 blockade of fexofenadine. Ann Allergy Asthma Immunol 1997;79:530-2.
18. 18. Abdelaziz MM, Devalia JL, Khair MA, Bayram H, Prior AJ, Davies RJ. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol 1998;101:410-20.
19. 19. Paul E, Berth-Jones J, Ortonne J-P, Stern M. Fexofenadine hydrochloride in the treatment of chronic idiopathic urticaria: a placebo-controlled, parallel-group, dose-ranging study. J Dermatol Treat 1998;9:143-9.
20. 20. Bernstein D, Schoenwetter W, Nathan R, Storms W, Ahlbrandt R, Mason J. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:443-8.
21. 21. Bronsky EA, Falliers CJ, Kaiser HB, Ahlbrandt R, Mason, J. Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist in the treatment of fall allergies. Allergy Asthma Proc 1998;19:135-41.
22. 22. Pratt C, Mason J, Russell T, Reynolds R, Ahlbrandt R. Cardiovascular safety of fexofenadine HCl. Am J Cardiol 1999;83:1451-4.
23. 23. Badoux A, Levy DA. Psychologic symptoms in asthma and chronic urticaria. Ann Allergy 1994;72:229-34.
24. 24. Thompson A, Finn A, Schoenwetter W. Effect of 60 mg bid fexofenadine HCl on quality of life, work productivity, and regular activity in patients with chronic idiopathic urticaria [abstract]. Ann Allergy Asthma Clin Immunol 1999;82):122.
25. 25. Finlay AY, Kahn GK. Dermatology Life Quality Index (DLQI) - a simple, practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6.
26. 26. Reilly MC, Zhrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-65.